DDX10 and myelodysplastic syndrome: Patient ALMA_14_PB (39–60 years, female; coverage 14.94x), with relapsed/refractory AML post-treatment, was accurately predicted as MDS-related secondary myeloid, confirmed genomically by detection of the DDX10-SKA3 fusion.